Different patterns of failure in two treatment regimens for primary central nervous system lymphoma, a retrospective analysis of 124 cases in Taiwan

• Published in: Clinical and experimental medicine 2023-12, Vol.23 (8), p.5327-5336
• Main Authors: Chuang, Chin-Hsuan, Kuo, Ming-Chung, Chang, Hung, Wu, Jin-Hou, Hung, Yu-Shin, Ou, Che-Wei, Lin, Tung-Liang, Su, Yi-Jiun, Ong, Yuen-Chin, Shih, Lee-Yung, Kao, Hsiao-Wen
• Format: Article
• Language: English
• Subjects: Antineoplastic Combined Chemotherapy Protocols; B-cell lymphoma; Central nervous system; Central Nervous System - pathology; Central Nervous System Neoplasms - pathology; Central Nervous System Neoplasms - therapy; Chemoradiotherapy; Hematology; Humans; Internal Medicine; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Nervous system; Oncology; Remission; Retrospective Studies; Risk assessment; Risk factors; Risk groups; Rituximab; Taiwan; Toxicity
• ISSN: 1591-9528; 1591-8890; 1591-9528
• DOI: 10.1007/s10238-023-01182-2

To explore prognostic factors and outcomes of primary central nervous system lymphoma (PCNSL) of diffuse large B-cell lymphoma (DLBCL) in Taiwan, 124 PCNSL-DLBCL patients (from 1995 to 2021) were retrospectively analyzed. Mainly, two treatment modalities including sandwich chemoradiotherapy and modified MATRix regimen were employed in these patients. Overall survival (OS) was determined by log-rank test and time-dependent Cox analysis. Median OS of all patients was 27.1 months. 47 (37.9%) patients who underwent sandwich chemoradiotherapy had a complete remission (CR) rate of 87.2%, median OS of 53.9 months, and progression free survival (PFS) of 42.9 months. 11 (8.9%) patients who underwent modified MATRix regimen had CR rate of 72.7%, median OS of 18.9, and PFS of 11.2 months. There are no significant OS differences between treatment groups or addition of Rituximab. Patients treated with the modified MATRix regimen experienced a higher early mortality rate followed by a survival plateau. IELSG low-risk group had significantly improved OS and PFS than IELSG intermediate- or high-risk group. In multivariant analysis, age > 60 years old and bilateral cerebral lesions are associated with significantly inferior OS. Sandwich chemoradiotherapy demonstrated better early survival and reduced treatment-related toxicity for PCNSL patients compared to the modified MATRix regimen. However, the long-term follow-up revealed a higher rate of treatment failure events in the sandwich chemoradiotherapy group. IELSG and MSKCC scores served as reliable risk assessment models. Incorporating bilateral cerebral lesions as a risk factor further improved risk evaluation.